Affitech contracts with ProBioGen for producer cell line generation for oncology antibody candidate
ProBioGen AG, and Affitech AS, jointly announced that they have entered into an agreement for a biopharmaceutical cell line to be developed by ProBioGen for high-level production of one of the lead candidates in Affitech's oncology therapeutic antibody pipeline.
Under the terms of the agreement, ProBioGen will apply its cell generation process for biopharmaceutical cell lines relying on the unique vectors and its pre-optimized CHO starter cell. This will be combined with automated cloning process to identify and develop a high producer line, which should be particularly suitable for a fed-batch development process. Financial details of the agreement have not been disclosed.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.